13
B2. One Prior Chemotherapy Regimen
➤ The evidence does not support the selection of a specific second-
line chemotherapy drug or combination based on age alone. This
recommendation has not changed. As stated in Recommendation A8,
age alone is not a contraindication to chemotherapy for NSCLC.
C1. Third-line Therapy
➤ 6.1. For the majority of patients with non-SCC, who received
chemotherapy with or without bevacizumab and immune checkpoint
inhibitor therapy (in either sequence), clinicians should offer the
options of single-agent pemetrexed or docetaxel or paclitaxel plus
bevacizumab in the third-line setting (Weak Recommendation; L).
D1. For Cytotoxic Therapy for Patients Who Have Received
Three Prior Regimens and Good PS
➤ Data are not sufficient to make a recommendation for or against
using cytotoxic drugs as fourth-line therapy. Patients should consider
experimental treatment, clinical trials, and continued best supportive
(palliative) care.
